

# $\beta$ 2AR-HIF-1 $\alpha$ -CXCL12 signaling of osteoblasts activated by isoproterenol promotes migration and invasion of prostate cancer cells

**Zhibin Huang**

Fujian Provincial Hospital

**Guihuan Li**

Southern Medical University

**Zhishuai Zhang**

Southern Medical University

**Ruonan Gu**

Southern Medical University

**Wenyang Wang**

Southern Medical University

**Xiaoju Lai**

Southern Medical University

**Zhong-kai Cui**

Southern Medical University

**Fangyin Zeng**

Southern Medical University

**Shiyuan Xu**

Southern Medical University

**Fan Deng** (✉ [fandeng@smu.edu.cn](mailto:fandeng@smu.edu.cn))

Southern Medical University <https://orcid.org/0000-0001-8069-3940>

---

## Research article

**Keywords:** chronic stress, cancer, bone metastasis, sympathetic nerve.

**Posted Date:** October 17th, 2019

**DOI:** <https://doi.org/10.21203/rs.2.11087/v2>

**License:**   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

**Version of Record:** A version of this preprint was published on November 26th, 2019. See the published version at <https://doi.org/10.1186/s12885-019-6301-1>.

# Abstract

**Background:** Chronic stress is well known to promote tumor progression, however, little is known on whether neurotransmitters released after chronic stress induced sympathetic activation regulate the function of osteoblasts to affect migration and invasion of metastatic cancer cells. **Methods:** First, the changes in migration and invasion ability of prostate cancer cell lines PC-3 and DU145 were assessed by transwell migration assay. PC-3 and DU145 cells proliferation ability were detected by CCK-8, and HIF-1 $\alpha$  expression of osteoblasts and the momentous proteins of epithelial-mesenchymal transition (EMT) of PC-3 and DU145 cells were examined by Western blot. Then, an analysis of the main cytokines associated with bone metastasis in osteoblasts and EMT-related biomarkers in PC-3 and DU145 cells was performed by qRT-PCR. Finally, rescue experiment was performed by using HIF-1 $\alpha$  siRNA and inhibitor, HIF-1 $\alpha$  overexpression plasmid,  $\beta$ 2-adrenergic receptor ( $\beta$ 2AR) inhibitor, CXCR4 siRNA and inhibitor. **Results:** In this study, isoproterenol (ISO), a non-selective  $\beta$ -adrenergic receptor ( $\beta$ AR) agonist, used as a pharmacological surrogate of sympathetic nerve activation induced by chronic stress, exhibited no direct effect on migration and invasion of PC-3 and DU145 prostate cancer cells. Whereas, osteoblasts pretreated with ISO promoted EMT and migration as well as invasion of PC-3 and DU145 cells, which was independent of promoting cell proliferation and could be inhibited by  $\beta$ 2AR inhibitor. Mechanically, ISO increased the secretion of CXCL12 via the  $\beta$ 2AR-HIF-1 $\alpha$  signaling in osteoblasts. Moreover, overexpression of HIF-1 $\alpha$  osteoblasts promoted migration and invasion of PC-3 and DU145 cells, which was inhibited by addition of recombinant knockdown of CXCR4 in PC-3 and DU145 cells, and inhibiting CXCL12-CXCR4 signaling with LY2510924 blunted the effects of osteoblasts in response to ISO on EMT and migration as well as invasion of PC-3 and DU145 cells. **Conclusions:** These findings indicate that  $\beta$ 2AR-HIF-1 $\alpha$ -CXCL12 signaling in osteoblasts facilitates migration and invasion as well as EMT of prostate cancer cells, and may play a potential role in affecting bone metastasis of prostate cancer.

## Background

Prostate cancer is the most commonly diagnosed cancer among men and the second leading cause of cancer death in the United States[1]. Emerging studies suggest that chronic psychological stress is a vital factor associated with poor clinical outcomes in cancer patients[2-4]. Meanwhile, b-blocker drugs that block b-adrenergic signaling involved in cancer progression may improve clinical outcomes of cancer patients[5, 6]. Accumulating evidence indicates that persistent secretion of stress-related hormones and neurotransmitters plays pivotal roles in the initiation and promotion of tumors[7]. Isoproterenol (ISO), a non-selective b-adrenergic receptor (bAR) agonist, used as a pharmacological surrogate of sympathetic nerve activation, promotes invasion and metastasis of tumors both *in vitro* and *in vivo*[8-10]. Previous studies demonstrated that central and sympathetic nervous systems activated by chronic stress promoted tumor metastasis through b2-adrenergic receptor (b2AR)[11].

Bone is a favored site for cancer cell metastasis[12]. The organ-specific nature of bone metastasis is now commonly agreed on not only a genetic determinant in tropism and the bone colonization process, but also the “seed and soil” theory to explain tumor cell tropism towards bone[12]. Osteoblasts also play a

key role in cancer bone metastasis[12]. In experimental animal models, mice were intracardially injected with bone-tropic prostate cancer cells. The lateral endocardial bone regions preferentially colonized by the prostate cancer cells were associated with a 5-fold higher number of osteoblasts compared to that in the medial endocortical regions[13]. Chemokine receptor type 4 (CXCR4) and C-X-C motif chemokine 12 (CXCL12) ligand are involved in the migration of various cancer cells[14, 15]. In healthy prostate epithelial cells, CXCR4 is not expressed, on the contrary, its expression level is significantly increased in invasive cancer cells[16]. Importantly, a previous study has shown that the CXCL12 (SDF-1)/CXCR4 signaling axis mediates prostate cancer cells homing to bone, as osteoblasts express the CXCL12 ligand and prostate cancer cells express the CXCR4 receptor[13].

The skeleton is richly vascularized and abundantly innervated with sympathetic nerves[17]. Sympathetic neurons are found in bone marrow, localize within cortical bone and regulate bone metabolism. Neurotransmitters released after sympathetic activation not only inhibit the proliferation of osteoblasts, but also stimulate cytokine secretion of osteoblasts including CXCL12 and RANKL (receptor activator of NF- $\kappa$ B ligand), which plays pivotal roles in stimulating osteoclast formation and hematopoietic cell trafficking[18-20]. However, little is known on whether neurotransmitters released after sympathetic activation regulate the function of osteoblasts to affect migration and invasion of metastatic cancer cells.

Herein, we demonstrated that osteoblasts stimulated by ISO promoted migration and invasion of prostate cancer cells in *in vitro* co-culture. We identified b2AR-HIF-1 $\alpha$ -CXCL12, involved in osteoblasts treated with ISO, as a signaling pathway that facilitated migration and invasion of prostate cancer cells, which could be inhibited by the b2AR-blockers ICI118,551 and CXCR4 inhibitor LY2510924.

## Methods

### Materials

Isoproterenol (ISO) and propranolol (Pro) were purchased from Abcam (Cambridge, MA, USA). ICI118,551, LY2510924 and YC-1 were supplied by MedChem Express (Monmouth Junction, NJ, USA). Antibodies were obtained from the following sources: rabbit polyclonal antibodies specific to E-cadherin and Vimentin from Proteintech Group, Inc. (Wuhan, China); mouse monoclonal antibody to  $\alpha$ -tubulin from Ray Antibody (Beijing, China); rabbit polyclonal antibodies to HIF-1 $\alpha$  from Cell Signaling Technology (Danvers, MA, USA); goat anti-rabbit or anti-mouse IgG-conjugated horseradish peroxidase from CWBiotech (Beijing, China). The siRNAs against mouse HIF-1 $\alpha$ , and control siRNA were provided by Genepharma Co, Ltd. DMEM/F-12, DMEM, 1% penicillin/streptomycin (P/S) and Minimum Essential Medium with Eagle Alpha modification ( $\alpha$ MEM) were purchased from Thermo Fisher Scientific (Waltham, MA, USA). fetal bovine serum (FBS) was obtained from Pan-Seratech (Heilbronn, Germany).

### Cell culture

Human prostate cancer cells PC-3 and DU145, mouse osteoblasts and MC3T3E1 cell lines were obtained from the Cell Bank, Chinese Academy of Sciences (Shanghai, China). PC-3 and DU145 cells were maintained in DMEM/F-12 and DMEM respectively, which were supplemented with 10% FBS and 1% P/S. Mouse MC3T3E1 cells were maintained in  $\alpha$ MEM supplemented with 10% FBS and 1% P/S. Cells were maintained at 37 °C in a 5% CO<sub>2</sub> atmosphere. To obtain osteoblast-conditioned medium (OBCM), cells were grown to 90% confluence and culture media were changed to  $\alpha$ MEM supplemented with 10% FBS with/without ISO. OBCM was collected two days after the medium change and stored at -80 °C until use.

### **Culture of primary mouse calvarial osteoblasts**

This study was approved by the Ethics Committee of Southern Medical University following the guidelines for the experimental use of animals. Twelve newborn ICR mice (1 day of age) were purchased from laboratory animal center (Southern Medical University, China), where they were kept in a sterile plastic cage under hygienic conditions. All animals used in this experiment were humanely euthanized by CO<sub>2</sub> asphyxiation before isolating Calvaria. Calvaria were isolated from 2–3-day old newborn mice. Collected bone tissue was digested 5 times using 0.1 mg/mL collagenase I (GIBCO BRL, Grand Island, NY, USA) in  $\alpha$ MEM with 1:40 diluted trypsin (Solarbio, Beijing, China). The cells isolated in the last 3 digestions were combined and cultured in  $\alpha$ MEM containing 10% FBS, 1% P/S.

### **Migration and invasion assays**

Assays were performed using 6.5-mm transwell inserts (24-well, 8  $\mu$ m pore size, Corning, NY, USA) pre-coated with/without 100  $\mu$ L Matrigel basement membrane matrix (BD Biosciences, San Jose, CA, USA) for migration and invasion assays, respectively. Primary osteoblasts or MC3T3E1 osteoblasts were grown to 90% confluence in 24-well tissue culture plates. In co-culture transwell assays, PC-3 and DU145 cells were cultured with serum-free DMEM/F-12 and DMEM, respectively, and MC3T3 E1 cells and primary osteoblasts were cultured with DMEM/F-12 or DMEM with 2.5% FBS. 24 h before migration, fresh 2.5% FBS DMEM containing 10 mM ISO (Abcam) or PBS was added to the cells. Primary osteoblasts or MC3T3E1 osteoblasts cell lines were pretreated with 50  $\mu$ M ICI118,551 (MedChem Express) for selective blocking b2AR. On the day of assays, PC-3 or DU145 cells were detached with trypsin and resuspended in DMEM supplemented with 10% FBS for 1 h prior to assay. For inhibiting the CXCR4, 50 nM LY2510924 (a CXCR4 inhibitor, MedChem Express) was applied for 30 min prior to assay. 500  $\mu$ L serum-free medium containing approximately  $1 \times 10^5$  cells was placed in the upper chamber. Plates were incubated for 12 h or 24 h at 37 °C in a 5% CO<sub>2</sub> incubator (Thermo Scientific, HERACELL 150i) for migration and invasion respectively. Unmigrated cells were removed with cotton-tipped swabs from the top of the membrane and the filters were washed with phosphate-buffered saline (PBS). Cells were fixed in 3.7% formaldehyde solution for 15 min and stained with 0.05% crystal violet in PBS for 30 min. Cells migrated were examined

and counted under a microscope (Nikon ECLIPSE TE2000-U). Quantification of migratory and invasive cells of five distinct images from each replicate per group was performed.

### **Western blotting assay**

Total protein from the cells was extracted with cold radio immunoprecipitation lysis buffer, protease inhibitor and phosphatase inhibitor cocktail (Cell Signaling Technology, Danvers, MA, USA). The protein samples were separated by 10% SDS-PAGE and transferred onto PVDF membranes (Millipore, Billerica, MA, USA), which was blocked with 5% skim milk prepared in PBS with Tween 20 (PBST). After blocking with 5% non-fat milk for 2 h at room temperature, the membranes were incubated with the following primary antibodies at 4 °C under gentle agitation overnight: E-cadherin (1:2000, 20874-I-AP; Proteintech), Vimentin (1:6000, 10366-I-AP; Proteintech),  $\alpha$ -tubulin (1:6000, RM2007; Ray Antibody), HIF-1a (1:1000, D2U3T; Cell Signaling Technology). Following washes in PBST 3 times, the membranes were incubated with goat anti-rabbit IgG-HRP (1:6000, CW0103; CWBiotech) or goat anti-mouse IgG-HRP (1:6000, CW0102; CWBiotech) for 1 h at room temperature. Protein expression was quantified by densitometric analysis using the ImageJ software (National Institutes of Health, Bethesda, MD, USA).

### **Cell proliferation assays**

Cell proliferation was determined using a Cell Counting Kit-8 (CCK-8, Beyotime Institute of Biotechnology, Shanghai, China) according to the manufacturer's instructions. For the CCK-8 assay,  $2 \times 10^4$  cells/well were seeded in a 96-well plate for 24 h and were treated with ISO or conditioned medium from MC3T3 E1/primary osteoblast with/without ISO, for 12 h and 24 h at 37°C. and the absorbencies at each time point were measured at 450nm by a microplate reader. All experiments were biologically repeated at least three times.

### **Quantitative real-time PCR (qRT-PCR)**

qRT-PCR was performed to determine the mRNA expression of *RANKL*, *CXCL12*, *CXCL16*, *WISP-1*, *Annexin II*, *TGF- $\beta$ 1*, *CXCR4*, *N-cadherin*, *Snail*, *Slug*, *Zeb-1*, *Twist-1*. Total RNA from the samples was isolated using RNAiso plus (TaKaRa, Kusatsu, Shiga, Japan), followed by reverse transcription with the HiScript II Q RT SuperMix kit (Vazyme, Nanjing, China). qPCR was conducted using 2 $\times$ T5 Fast qPCR Mix SYBR Green (Tsingke, Beijing, China) and run with the Applied Biosystems 7500 Fast Real-Time PCR System (Applied Biosystems). PCR conditions included an initial denaturation step of 3 min at 95 °C, followed by 40 cycles of PCR consisting of 30 s at 95 °C, 30 s at 60 °C, and 30 s at 72 °C. The PCR data were analyzed by the  $2^{-\Delta\Delta CT}$  method (Livak and Schmittgen, 2001). All mouse primer sequences used are as follows, Mouse *RANKL* (5'- AGCCGAGACTACGGCAAGTA-3' and 5'- AAAGTACAGGA

ACAGAGCGATG-3'); Mouse *CXCL12* (5'-TGCATCAGTGACGGTAAACCA-3' and 5'-CACAGTTTGGAGTGTTGAGGAT-3'); Mouse *CXCL16* (5'- CCTTGTCTCTTGC

GTTCTTCC-3' and 5'- TCCAAAGTACCCTGCGGTATC-3'); Mouse *Annexin II*(5'-ATGTCTACTGTCCACGAAATCCT-3' and 5'- TGACTGACCCGTAGGCACTT-3'); Mouse *TGF- $\beta$ 1* (5'-CTGGCGAGCCTTAGTTTGGAC-3' and 5'- TGACTGACCCGTAGGCACTT-3'); Mouse *WISP-1* (5'-ACTGGGCGTCAGCCTAATC-3' and 5'-CCCCACTGTAATCGCAGTAGAG-3'); Mouse *GAPDH* (5'-AGGTCGGTGTGAACGGATTTG -3' and 5'- GGGGTCGTTGATGGCAACA -3'); Human *CXCR4* (5'-GAACTTCCTATGCAGGCAGTCC-3' and 5'-CCATGATGC TGAAACTGAAC-3'); Human *N-cadherin* (5'-TCAGGCGTCTGTAGAGGCTT-3' and 5'- ATGCACATC

CTTCGATAAGACTG-3'); Human *Snail* (5'- TCGGAAGCCTAACTACAGCGA-3'); Human *Slug* (5'-CGAACTGGACACACATACAGTG-3' and 5'- CTGAGGATCTCT

GGTTGTGGT-3'); Human *Zeb-1* (5'- GATGATGAATGCGAGTCAGATGC-3' and 5'-ACAGCAGTGTCTTGTTGTTGT-3'); Human *Twist-1* (5'- GTCCGCAGTCTTACGAGGAG-3' and 5'-GCTTGAGGGTCTGAATCTTGCT-3'); Human *GAPDH* (5'- GGAGCGAGATCCCTCCAAAAT-3' and 5'-GGCTGTTGTCATACTTCTCATGG-3').

## Transient siRNA Silencing

The three specific siRNAs (*HIF- $\alpha$*  siRNA, *CXCR4* siRNA and negative control siRNA) were designed by GenePharma (Shanghai, China). Transient silencing of *HIF- $\alpha$*  and *CXCR4* was achieved by transfection of siRNA oligos using Lipofectamine™ 3000 reagent (Invitrogen) following the manufacturer's instructions. Briefly, 50,000 cells/cm<sup>2</sup> were plated into 6-well plates and allowed to adhere for 24 h. Subsequently, 5  $\mu$ l of siRNA was added to 500  $\mu$ l of Opti-MEM (Gibco; Thermo Fisher Scientific, Inc.) thoroughly mixed, and incubated at room temperature for 5 min. Lipofectamine™ 3000 (5  $\mu$ l; Gibco; Thermo Fisher Scientific, Inc.) was added to 500  $\mu$ l of Opti-MEM, thoroughly mixed and incubated at room temperature for 5 min. The diluted siRNA and diluted Lipofectamine™ 3000 were mixed and incubated at room temperature for 15 min. The siRNA/Lipofectamine mixture was transferred into 6-well plates at 1000  $\mu$ l/well. The cells were maintained for 6 h at 37°C. Following replacement of the culture medium, the cells were incubated for an additional 24–72 h. *HIF- $\alpha$*  siRNA and *CXCR4* knockdown were verified using qRT-PCR and western blot analyses. All siRNA sequences used are as follows, *HIF- $\alpha$*  siRNA sequence (sense 5'-GUGGUUUUUAUUCAGCACGATT-3' , antisense 5'-UCGUGCUGAAUAAUACCACTT-3'), *CXCR4* siRNA (sense 5'-CUGUCCUGC UAUUGCAUUATT-3', antisense 5'-UAAUGCAAUAGCAGGACAGTT-3') and negative control siRNA sequence (sense 5'-UUCUUCGAACGUGUCACGUTT-3', antisense 5'-ACGUGACACGUUCGGAGAATT-3').

## Transfection with HIF-1 $\alpha$ overexpression vector

The HIF-1 $\alpha$  overexpression plasmid, a generous gift provided by Dr Ruonan Gu (Zhujiang Hospital, Southern Medical University, Guangzhou, China), was used for transfection. MC3T3 E1 and primary osteoblast cells ( $3 \times 10^5$  cells/well) were seeded into 6-well plates and allowed to grow at 50–70% confluence. The cells were transfected with HIF-1 $\alpha$  plasmid and vector control using Lipofectamine<sup>TM</sup> 3000, according to the manufacturer's instructions. After 6 h, the original medium was replaced with fresh complete medium. The expression of HIF-1 $\alpha$  was determined by Western blotting after 48–72 h.

## ELISA assays

ELISA assays for CXCL12 (Cat. No. RK00168, ABclonal Technology) were performed according to the manufacturer's instructions. In brief, cell culture supernates from MC3T3E1 and primary osteoblasts were centrifuged at 1000 *g* for 10 min and detected: (a) preparing the standard and reagents; (b) washing plates 4 times; (c) adding 100  $\mu$ L of standards and test samples to each well; (d) adding 100  $\mu$ L Biotin-Conjugate antibody working solution; (e) adding 100  $\mu$ L Streptavidin-HRP working solution; (f) adding 100  $\mu$ L substrate solution; (g) adding 100  $\mu$ L stop solution; (h) adding 100  $\mu$ L stop solution; (i) detecting the optical density within 5 min under 450 nm.

## Statistics

All of the experiments were at least done in triplicates individually, unless otherwise stated. The data are presented as mean  $\pm$  standard error of the mean (SEM). Data were analyzed by comparing the means using one-way ANOVA followed by Dunnett's test or two-way ANOVA followed by Bonferroni's *post hoc* test or a *t*-test. For all analyses,  $P < 0.05$  was considered statistically significant.

## Results

### Isoproterenol-simulated sympathetic nerve activation presents no direct effect on migration and invasion of prostate cancer cells.

A cancer diagnosis in itself identified as a major distress factor causes anxiety and depression[21]. As chronic stress has been linked to cancer progression[7-9], whether increasing stress hormone in sympathetic outflow, typically caused by chronic stress, could directly alter migration and invasion of prostate cancer cells is of particular interest. Therefore, we first determined whether 10  $\mu$ M isoproterenol(ISO), a non-selective  $\beta$ AR agonist as a pharmacological surrogate of sympathetic nerve activation[8], increased migration and invasion of human prostate cancer cells, namely PC-3 and DU145. As shown in Figure 1A-B, when PC-3 and DU145 cells were plated in the transwell filter, 10  $\mu$ M ISO

treatment did not increase the number of cells that migrated or invaded through transwell insert , indicating that 10  $\mu$ M ISO has no direct effect on migration and invasion of prostate cancer cells.

### **Osteoblasts triggered by ISO promote migration and invasion of prostate cancer cells independent of promoting proliferation.**

Prostate cancer is a cancer type that frequently metastasizes to bone and preferentially colonizes to osteoblast-rich area in early stages[12]. Activation of sympathetic nervous system modulated the bone marrow microenvironment, building a receptive niche for metastatic colonization of breast cancer cells[10]. Therefore, we explored whether osteoblasts contributed to the effect of sympathetic activation on prostate cancer metastasis to bone. In MC3T3 E1-PC-3/DU145 co-culture transwell assays, MC3T3E1 obviously increased migration and invasion of PC-3 and DU145 cells plated on the transwell filter, while MC3T3E1 pretreated with ISO for 24 h significantly exacerbated migration and invasion of PC-3 and DU145 cells towards to MC3T3E1 cells (Figure 2A and B). ISO treatment of MC3T3 E1, prior to the addition of 10  $\mu$ M propranolol (Pro)-treated PC-3 or DU145 cells to the transwell filters (in order to block  $\beta$ AR signaling specifically in cancer cells), did not inhibit cell migration and invasion signifying that the effects of ISO on migration and invasion of PC-3/DU145 cells are mediated by osteoblasts (Figure 2A and B). Consistent results were obtained for testing migration and invasion of PC-3 and DU145 cells co-culture with primary osteoblasts (Figure 2C). To further explore whether these effects are mediated by promoting cell proliferation, PC-3 and DU145 were cultured with conditioned medium from MC3T3 E1/primary osteoblasts with/without ISO for 12 h and 24 h that was consistent with the time points of invasion and migration. As shown in Figure S1, treated with ISO and cultured with conditioned medium from MC3T3 E1/primary osteoblast with/without ISO did not promote proliferation of PC-3 and DU145 cells at 12 h and 24 h. These findings suggest that the enhancement effects of osteoblasts triggered by ISO on migration and invasion of PC-3 and DU145 cells are independent of promoting proliferation.

### **Inhibition of $\beta$ 2AR signaling in osteoblasts antagonizes migration and invasion of prostate cancer cells induced by osteoblasts triggered with ISO.**

$\beta$ 2-adrenergic receptor ( $\beta$ 2AR) is present, rather than other adrenergic receptors, in primary mouse osteoblasts[20]. ISO binds  $\beta$ 2AR of osteoblasts to modulate cell function[22-25]. To investigate whether  $\beta$ 2AR signaling is essential for the effects of osteoblasts pretreated with ISO on migration and invasion of prostate cancer cells, we treated osteoblasts with ISO combined with/without ICI (ICI118,551, a selective  $\beta$ 2AR antagonist). We found that MC3T3E1 treated with ISO markedly increased the number of migratory and invasive PC-3 and DU145 cells compared with control groups. However, treatment with ICI118,551 blocked the effects of MC3T3E1 induced by ISO on promoting migration and invasion of PC-3 and DU145 cells (Figure 3A). Consistent results were obtained for testing migration and invasion of PC-3 and DU145 cells co-cultured with primary osteoblasts (Figure 3B). These findings suggest that

osteoblasts treated with ISO to promote migration and invasion of prostate cancer cells is mediated by  $\beta$ 2AR signaling in osteoblasts.

### **Conditioned medium (CM) from osteoblasts treated with ISO induces EMT of prostate cancer cells.**

Epithelial–mesenchymal transition (EMT), that is a physiological process during embryonic development, plays crucial roles in regulating the differentiation of multiple tissues and organs. In addition, growing evidence demonstrated that EMT was a phenotypic conversion linked to invasion and metastasis *in vitro* and *in vivo*, respectively[26-30]. Therefore, an analysis of the main EMT bio-markers, named E-cadherin and Vimentin, was performed in PC-3 and DU145 cells treated with ISO or CM from MC3T3 E1/primary osteoblasts for 24 h. No difference of E-cadherin and Vimentin expression was observed between the control and ISO treated groups (Figure 4A). However, CM from MC3T3E1 in response to ISO significantly downregulated the expression of E-cadherin as well as upregulated the expression of Vimentin in PC-3 and DU145 cells, which was inhibited by selective  $\beta$ 2AR antagonist, ICI118,551 (Figure 4B). PC-3 and DU145 cells treated with CM collected from primary osteoblasts in response to ISO showed consistent results (Figure 4C). These findings indicate that osteoblasts treated with ISO induce the EMT of PC-3 and DU145 cells, which is inhibited by  $\beta$ 2AR antagonist.

### **ISO increases the secretion of CXCL12 via $\beta$ 2AR-HIF-1a signaling in osteoblasts.**

In order to unveil the molecular mechanisms underlying the osteoblast-mediated modulation of cell migration and invasion in response to ISO, an analysis of the main cytokines associated with bone metastasis was performed in MC3T3E1 and primary osteoblasts. ISO significantly increased *CXCL12* expression in MC3T3E1 (Figure 5A) as well as primary osteoblasts compared with control groups (Figure 5B). Similar results at the CXCL12 protein level examined by ELISA was presented in Figure 5C. HIF-1a-CXCL12 signaling in osteoblast-lineage cells promotes systemic breast cancer growth and metastasis in mice[31]. To test the possibility of that HIF-1a signaling might contribute to the upregulation of CXCL12 expression level in osteoblasts treated with ISO, we analyzed HIF-1a expression in osteoblasts by Western-blotting. ISO significantly increased the expression of HIF-1a in MC3T3E1 and primary osteoblasts, which was blunted by ICI118,551, a selective  $\beta$ 2AR antagonist (Figure 5D and E). Furthermore, addition of recombinant YC-1, a HIF-1a antagonist, blocked the effect of ISO on CXCL12 expression in MC3T3E1 and primary osteoblasts (Figure 5F). Consistently, HIF-1a knockdown significantly reduced CXCL12 expression in MC3T3E1 and primary osteoblasts treated with ISO (Figure 5G), indicating that HIF-1a is the key transcription factor affecting the secretion of CXCL12 in osteoblasts treated with ISO. These findings suggest that  $\beta$ 2AR-HIF-1a signaling mediates the expression of CXCL12 in osteoblasts treated with ISO.

## **HIF-1 $\alpha$ -CXCL12 signaling in osteoblasts mediates the ISO stimulatory effect of osteoblasts on the EMT and migration as well as invasion of prostate cancer cells.**

CXCL12 is a well-known C-X-C chemokine and binds to CXCR4 that can regulate multiple functions of cells[32]. In bone marrow, CXCL12, mainly produced by osteoblasts, binds to CXCR4 and regulates the migration of CD34<sup>+</sup> cells[33]. CXCR4 is absent in healthy prostate epithelial cells, while its expression level is significantly upregulated in PC-3 and DU145 cells[34-36]. Current evidence, accompanied by the observation that ISO strongly increases the expression of CXCL12 in osteoblasts (Figure 5A-C) encouraged us to further explore whether this cytokine contributes to the effect of osteoblasts treated with ISO on migration and invasion of prostate cancer cells. In co-culture transwell assay, overexpression of HIF-1 $\alpha$  in MC3T3E1 significantly promoted migration and invasion of PC-3 and DU145 cells compared with control groups, which was inhibited by addition of recombinant knockdown of CXCR4 in PC-3 and DU145 cells(Figure 6A-C). Similar results were obtained by co-culturing PC-3 or DU145 cells with primary osteoblasts, respectively (Figure 6D). Additionally, MC3T3E1 and primary osteoblast dosed with ISO significantly promoted migration and invasion of PC-3 and DU145 cells compared with control groups, which was inhibited by blocking CXCR4 in PC-3 and DU145 cells with LY2510924, an inhibitor of CXCR4 (Figure S2A-D). Moreover, CM from MC3T3E1 and primary osteoblasts dosed with ISO significantly decreased the expression of E-cadherin and increased the expression of Vimentin in PC-3 and DU145 cells, which was inhibited by LY2510924 (Figure S3A-B). Meanwhile, CM from MC3T3E1 and primary osteoblasts treated with ISO significantly upregulated the expression of *Snail* and *N-cadherin* that are EMT-related biomarkers. These findings indicate that HIF-1 $\alpha$ -CXCL12 in osteoblasts is the key signaling involved in migration and invasion of prostate cancer cells towards osteoblasts treated with ISO.

## **Discussion**

The tumor metastatic efficiency depends on its genetic and phenotypic make-up as well as the receptive microenvironment for tumor colonization, establishment, and growth in distant sites. In the case of prostate cancer, host-derived factors within the bone microenvironment are essential for the establishment of cancer cells in bone[37]. However, little is known about the conditions and factors that regulate the bone microenvironment to affect cancer-bone metastasis. Sympathetic nerves releasing norepinephrine are present within tumors and their microenvironment, which can regulate gene expression and cellular functions in the tumor microenvironment through various pathways. Aberrant activation of sympathetic nerves promotes the growth, invasion, and metastasis of tumors[7]. Although several studies have highlighted the stimulatory effects of stress-related hormones on migration of prostate cancer cells[38, 39], the results of our study showed that ISO, a non-selective  $\beta$ AR agonist, presented no direct effect on migration and invasion of human prostate cancer PC-3 and DU145 cells. One possible explanation for this result could be the time point selected for the analysis (12 h), which was likely later than the time interval for ISO affecting on cell migration in our culture conditions. The other might be that different stress-related hormones (e.g. ISO, norepinephrine, adrenaline etc.) and detection methods (transwell assay, cell scratch test etc.) were used in migration assay. Additionally, the

b2AR expression level of prostate cancer cells plays a key role in the entire metastatic process, including its effects on the phenotype of the prostate cells and thereby their ability to migrate and invade, and probably also their colonization at the metastatic site[40]. Low expression of  $\beta$ 2AR in prostatic epithelial cells is associated with a mesenchymal-like phenotype[41], indicating that these cells may have the potential to colonize at the metastatic site. To what extent this effect on the metastasis of prostate cancer remains unclear. We are interested in investigating this point in our future study.

Cancer diagnosis induces chronic stress that thereby promotes the progression of cancer in patients[2, 3]. However, in our present study, 10 $\mu$ M ISO, a pharmacological surrogate of chronic stress *in vitro*, shows no direct effect on migration and invasion of prostate cancer cells. These suggest that there are some other pathways to mediate chronic stress promoting the metastasis of prostate cancer. In the bone microenvironment, osteoblasts contribute to bone disease and remodeling[42]. Additionally, the uniform distribution of the osteoblast lineage within the bone may contribute to cancer cell colonization and adhesion during bone metastasis of prostate cancer[13]. Moreover, the bone marrow microenvironment stimulated by activation of sympathetic nerves facilitates cancer cells to disseminate to and colonize in bone [10]. In the present study, we found that osteoblasts treated with ISO promoted migration and invasion of human prostate cancer PC-3 and DU145 cells. On the other hand, we showed that b2AR activation in osteoblasts predominantly accounted for the stimulatory effect of ISO on migration and invasion of prostate cancer cells. This was supported by the observation that MC3T3E1 and osteoblasts pretreated with ISO for 24 h could promote migration and invasion of PC-3 and DU145 cells. In our experimental setting, although cancer cells were directly subjected to ISO stimulation, PC-3 and DU145 cells were pretreated with propranolol for 30 min, which presented no effects on migration and invasion of prostate cancer cells induced by osteoblasts in response to ISO. Our results also showed that CM from osteoblast with/without ISO presented no effect on proliferation of prostate cancer cells. Therefore, the stimulatory effect of osteoblasts treated with ISO on migration and invasion of prostate cancer cells, which is independent of promoting proliferation, must occur *via* stimulation of the b2AR in osteoblasts, rather than *via* a direct effect on prostate cancer cells. Additionally, it is reported that cancer cells inoculation in mice pretreated with ISO for 14 days can increase the number of bone lesions and tumors, and stimulation of the b2AR in host stromal cells mediated the stimulatory effect of ISO on breast cancer cell-bone metastasis[10], suggesting that b2AR signaling in osteoblasts is essential for cancer cell metastasis to bone. Importantly, study *in vivo* by selective deletion of the b2AR in osteoblasts is required to further confirm the results in our future work. EMT, which is a biological process and responsible for migration and invasion of cancer cells, promotes tumor metastasis[43, 44]. We hypothesized that osteoblasts treated with ISO contributed to migration and invasion of prostate cancer cells by inducing EMT. In this study, we demonstrated that CM from osteoblasts in response to ISO downregulated the expression of *E-cadherin*, while upregulated the expression of *Vimentin*, *Snail* and *E-cadherin* in human prostate cancer PC-3 and DU145 cells. These data support that osteoblasts treated with ISO promote migration and invasion probably *via* inducing EMT in prostate cancer cells.

CXCL12 is a well-known bone marrow-derived C-X-C chemokine and a pre-B cell growth stimulating factor. Previous researches have reported that CXCL12/CXCR4 axis plays a critical role in prostate cancer

progression. Over the last few years, it has been well acknowledged that the levels of CXCL12 in human and mouse tissues were higher in the preferable sites of metastasis for prostate cancer cells (e.g., bone, liver, and kidney), compared with that in tissues rarely affected (e.g., lung, tongue, and eye)[45]. Wang and collaborators showed that by disrupting cellular interactions mediated by the CXCR4/CXCL12 axis with the CXCR4 inhibitor AMD3100, the preferential homing pattern of prostate cancer cells to osteoblast-rich bone surfaces was disrupted[13]. In the present study, we found that knockdown of CXCR4 in PC-3 and DU145 cells reduced migration and invasion of PC-3 and DU145 cells towards osteoblasts with overexpression of HIF-1 $\alpha$ . We also found that CXCR4 inhibitor LY2510924 reduced migration and invasion of PC-3 and DU145 cells towards osteoblasts in response to ISO. These suggest that HIF-1 $\alpha$ -CXCL12 signaling axis in osteoblasts is probably employed by metastatic prostate cancer cells as well as their bone metastatic potential induced by sympathetic activation. Regardless of the pathophysiological factor(s) increasing its expression or activity, our findings further reinforce that CXCL12 is one of the most important “soil” factors that facilitates the metastasis of bone by prostate cancer cells. The level of HIF-1 $\alpha$  expression, as a tissue hypoxia index product, will increase during tissue hypoxia. HIF-1 $\alpha$  signaling is one of the key pathways to mediate various cancer progression. Previous research/ers reported that selective deletion of the HIF-1 $\alpha$  in osteoblast-lineage cells suppressed metastasis to bone[31]. Previous studies have shown that ISO can promote the expression of HIF-1 $\alpha$  in a variety of cells, which was independent of hypoxia-like environment. In our study[46-48], we found that HIF-1 $\alpha$  mediated the effect of ISO on osteoblasts to enhance the secretion of CXCL12, indicating that HIF-1 $\alpha$  signaling of osteoblasts may mediate prostate cancer bone metastasis in response to sympathetic activation. Further studies are needed to explore the mechanism of ISO-induced HIF-1 $\alpha$  expression in osteoblasts.

Despite the limitations of the *in vitro* model employed, our present study reinforces the role of osteoblasts and their secreted bioactive molecules in the bone microenvironment as key modulators of cancer metastasis to bone. Osteoblast-derived CXCL12 in response to ISO promotes migration and invasion of prostate cancer cells. This supports the role of sympathetic signaling in bone metastatic process[10], and the use of b-blockers as possible adjuvant therapy for prostate cancer patients[49, 50]. Whether b2AR signaling of osteoblast promotes the recruitment of circulating metastatic prostate cancer cells into bone remains to be determined. Importantly, it is reported that the beneficial effect of b-blockers on disease-free survival and overall survival in the epidemiological or perioperative setting remains variable, tumour-specific, and of few evidences at present[51]. Although we have identified b2AR-HIF-1 $\alpha$ -CXCL12 signaling axis in osteoblasts as a key factor to promote migration and invasion of prostate cancer cells, whether this signaling axis plays the similar role in other tumors is still unclear, which requires further *in vivo* experiments.

## Conclusions

In summary, these results provide evidence in support of the central role of osteoblasts in regulating bone metastasis of prostate cancer. We demonstrate that osteoblasts treated with ISO, a pharmacological surrogate of sympathetic nerve activated by chronic stress and depression, promoted migration and invasion of prostate cancer cells. We delineated that this effect on migration and invasion of prostate

cancer cells, which is independent of promoting proliferation was mediated *via* b2AR in osteoblasts, rather than through a direct effect on cancer cells. Furthermore, the expression of CXCL12 induced by ISO *via* b2AR-HIF-1a signaling in osteoblasts, regulates this effect *via* CXCR4 in prostate cancer cells (Figure 7). This study contributes to our understanding of the prometastatic role of osteoblasts in patients with prostate cancer in response to chronic stress, and provides a possibility of using b2AR antagonist or CXCR4 inhibitor to treat prostate cancer in clinic.

## Abbreviations

**CXCL12**, chemokine (C-X-C motif) ligand 12; **CXCL16**, chemokine (C-X-C motif) ligand 16; **CXCR4**, chemokine (C-X-C motif) receptor type 4; **EMT**, epithelial-mesenchymal transition; **GAPDH**, glyceraldehyde-3-phosphate dehydrogenase; **HIF-1a**, hypoxia inducible factor-1 alpha; **SDF-1**, stromal cell-derived factor 1; **RANKL**, receptor activator of NF- $\kappa$ B ligand; **TGF- $\beta$ 1**, transforming growth factor- $\beta$ 1; **WISP-1**, Wnt1-inducible signaling pathway protein 1.

## Declarations

### *Ethics approval and consent to participate*

Mice were bred and housed in accordance with animal welfare rules in a pathogen-free facility. This study was approved by the Ethics Committee of Southern Medical University following the guidelines for the experimental use of animals.

### *Consent for publication*

Not applicable.

### *Availability of data and materials*

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

### *Competing interests*

The authors declare that they have no competing interests" in this section.

### *Funding*

This work was supported financially by the National Natural Science Foundation of China (Grant No. 81772761, 81672540, 81472407); Science and Technology Foundation of Guangzhou in China (Grant No. 201607010351,210707010303). Funding bodies did not have any influence in the design of the study and data collection, analysis and interpretation of data or in writing the manuscript.

### *Author contributions*

ZH designed and conducted the experiments, performed data analysis, and wrote the manuscript. GL, ZZ, RG, WW, XL, WZ and HZ performed experiments and data analysis. ZC wrote the manuscript. FZ, SX and FD designed the study, interpreted the data, wrote the manuscript, and approved the final version of the manuscript for publication. All authors read and approved the final manuscript.

### ***Acknowledgements***

Not applicable.

## **References**

1. DeSantis CE, Siegel RL, Sauer AG, Miller KD, Fedewa SA, Alcaraz KI, Jemal A: Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities. *CA Cancer J Clin* 2016, 66(4):290-308.
2. Armer JS, Clevenger L, Davis LZ, Cuneo M, Thaker PH, Goodheart MJ, Bender DP, Dahmouch L, Sood AK, Cole SW *et al*: Life stress as a risk factor for sustained anxiety and cortisol dysregulation during the first year of survivorship in ovarian cancer. *Cancer* 2018, 124(16):3401-3408.
3. Blanc-Lapierre A, Rousseau MC, Parent ME: Perceived Workplace Stress Is Associated with an Increased Risk of Prostate Cancer before Age 65. *Front Oncol* 2017, 7:269.
4. Fox JP, Philip EJ, Gross CP, Desai RA, Killelea B, Desai MM: Associations between mental health and surgical outcomes among women undergoing mastectomy for cancer. *Breast J* 2013, 19(3):276-284.
5. Udumyan R, Montgomery S, Fang F, Almroth H, Valdimarsdottir U, Ekblom A, Smedby KE, Fall K: Beta-Blocker Drug Use and Survival among Patients with Pancreatic Adenocarcinoma. *Cancer Res* 2017, 77(13):3700-3707.
6. Perron L, Bairati I, Harel F, Meyer F: Antihypertensive drug use and the risk of prostate cancer (Canada). *Cancer Causes Control* 2004, 15(6):535-541.
7. Cole SW, Nagaraja AS, Lutgendorf SK, Green PA, Sood AK: Sympathetic nervous system regulation of the tumour microenvironment. *Nature Reviews Cancer* 2015, 15(9):563-572.
8. Mulcrone PL, Campbell JP, Clement-Demange L, Anbinder AL, Merkel AR, Brekken RA, Sterling JA, Eleftheriou F: Skeletal Colonization by Breast Cancer Cells Is Stimulated by an Osteoblast and beta2AR-Dependent Neo-Angiogenic Switch. *J Bone Miner Res* 2017.
9. Chen H, Liu D, Guo L, Cheng X, Guo N, Shi M: Chronic psychological stress promotes lung metastatic colonization of circulating breast cancer cells by decorating a pre-metastatic niche through activating beta-adrenergic signaling. *J Pathol* 2018, 244(1):49-60.
10. Campbell JP, Karolak MR, Ma Y, Perrien DS, Masood-Campbell SK, Penner NL, Munoz SA, Zijlstra A, Yang X, Sterling JA *et al*: Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice. *PLoS Biol* 2012, 10(7):e1001363.
11. Shi M, Liu D, Yang Z, Guo N: Central and peripheral nervous systems: master controllers in cancer metastasis. *Cancer Metastasis Rev* 2013, 32(3-4):603-621.

12. Shupp AB, Kolb AD, Mukhopadhyay D, Bussard KM: Cancer Metastases to Bone: Concepts, Mechanisms, and Interactions with Bone Osteoblasts. *Cancers (Basel)* 2018, 10(6).
13. Wang N, Docherty FE, Brown HK, Reeves KJ, Fowles AC, Ottewell PD, Dear TN, Holen I, Croucher PI, Eaton CL: Prostate cancer cells preferentially home to osteoblast-rich areas in the early stages of bone metastasis: evidence from in vivo models. *J Bone Miner Res* 2014, 29(12):2688-2696.
14. Sleightholm RL, Neilsen BK, Li J, Steele MM, Singh RK, Hollingsworth MA, Oupicky D: Emerging roles of the CXCL12/CXCR4 axis in pancreatic cancer progression and therapy. *Pharmacol Ther* 2017, 179:158-170.
15. Saha A, Ahn S, Blando J, Su F, Kolonin MG, DiGiovanni J: Proinflammatory CXCL12-CXCR4/CXCR7 Signaling Axis Drives Myc-Induced Prostate Cancer in Obese Mice. *Cancer Res* 2017, 77(18):5158-5168.
16. Shen PF, Chen XQ, Liao YC, Chen N, Zhou Q, Wei Q, Li X, Wang J, Zeng H: MicroRNA-494-3p targets CXCR4 to suppress the proliferation, invasion, and migration of prostate cancer. *Prostate* 2014, 74(7):756-767.
17. Elefteriou F: Neuronal signaling and the regulation of bone remodeling. *Cell Mol Life Sci* 2005, 62(19-20):2339-2349.
18. Elmquist JK, Strewler GJ: Physiology: do neural signals remodel bone? *Nature* 2005, 434(7032):447-448.
19. Elefteriou F, Ahn JD, Takeda S, Starbuck M, Yang XL, Liu XY, Kondo H, Richards WG, Bannon TW, Noda M *et al*: Leptin regulation of bone resorption by the sympathetic nervous system and CART. *Nature* 2005, 434(7032):514-520.
20. Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, Armstrong D, Ducy P, Karsenty G: Leptin regulates bone formation via the sympathetic nervous system. *Cell* 2002, 111(3):305-317.
21. Ullrich PM, Carson MR, Lutgendorf SK, Williams RD: Cancer fear and mood disturbance after radical prostatectomy: consequences of biochemical evidence of recurrence. *J Urol* 2003, 169(4):1449-1452.
22. Mulcrone PL, Campbell JP, Clement-Demange L, Anbinder AL, Merkel AR, Brekken RA, Sterling JA, Elefteriou F: Skeletal Colonization by Breast Cancer Cells Is Stimulated by an Osteoblast and beta2AR-Dependent Neo-Angiogenic Switch. *J Bone Miner Res* 2017, 32(7):1442-1454.
23. Katsumura S, Ezura Y, Izu Y, Shirakawa J, Miyawaki A, Harada K, Noda M: Beta Adrenergic Receptor Stimulation Suppresses Cell Migration in Association with Cell Cycle Transition in Osteoblasts-Live Imaging Analyses Based on Fucci System. *J Cell Physiol* 2016, 231(2):496-504.
24. Yamada T, Ezura Y, Hayata T, Moriya S, Shirakawa J, Notomi T, Arayal S, Kawasaki M, Izu Y, Harada K *et al*: beta(2) adrenergic receptor activation suppresses bone morphogenetic protein (BMP)-induced alkaline phosphatase expression in osteoblast-like MC3T3E1 cells. *J Cell Biochem* 2015, 116(6):1144-1152.
25. Kawai M, Kinoshita S, Shimba S, Ozono K, Michigami T: Sympathetic activation induces skeletal Fgf23 expression in a circadian rhythm-dependent manner. *J Biol Chem* 2014, 289(3):1457-1466.

26. Thiery JP, Acloque H, Huang RY, Nieto MA: Epithelial-mesenchymal transitions in development and disease. *Cell* 2009, 139(5):871-890.
27. Zhang X, Cui P, Ding B, Guo Y, Han K, Li J, Chen H, Zhang W: Netrin-1 elicits metastatic potential of non-small cell lung carcinoma cell by enhancing cell invasion, migration and vasculogenic mimicry via EMT induction. *Cancer Gene Ther* 2018, 25(1-2):18-26.
28. Xiang J, Fu X, Ran W, Wang Z: Grhl2 reduces invasion and migration through inhibition of TGFbeta-induced EMT in gastric cancer. *Oncogenesis* 2017, 6(1):e284.
29. Wang L, Wu H, Wang L, Zhang H, Lu J, Liang Z, Liu T: Asporin promotes pancreatic cancer cell invasion and migration by regulating the epithelial-to-mesenchymal transition (EMT) through both autocrine and paracrine mechanisms. *Cancer Lett* 2017, 398:24-36.
30. Catalano M, D'Alessandro G, Lepore F, Corazzari M, Caldarola S, Valacca C, Faienza F, Esposito V, Limatola C, Cecconi F *et al*: Autophagy induction impairs migration and invasion by reversing EMT in glioblastoma cells. *Mol Oncol* 2015, 9(8):1612-1625.
31. Devignes CS, Aslan Y, Brenot A, Devillers A, Schepers K, Fabre S, Chou J, Casbon AJ, Werb Z, Provot S: HIF signaling in osteoblast-lineage cells promotes systemic breast cancer growth and metastasis in mice. *Proc Natl Acad Sci U S A* 2018, 115(5):E992-E1001.
32. Sun X, Cheng G, Hao M, Zheng J, Zhou X, Zhang J, Taichman RS, Pienta KJ, Wang J: CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression. *Cancer Metastasis Rev* 2010, 29(4):709-722.
33. Jung Y, Wang J, Schneider A, Sun YX, Koh-Paige AJ, Osman NI, McCauley LK, Taichman RS: Regulation of SDF-1 (CXCL12) production by osteoblasts; a possible mechanism for stem cell homing. *Bone* 2006, 38(4):497-508.
34. Darash-Yahana M, Pikarsky E, Abramovitch R, Zeira E, Pal B, Karplus R, Beider K, Avniel S, Kasem S, Galun E *et al*: Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. *Faseb j* 2004, 18(11):1240-1242.
35. Benslimane-Ahmim Z, Pereira J, Lokajczyk A, Dizier B, Galy-Fauroux I, Fischer AM, Heymann D, Boisson-Vidal C: Osteoprotegerin regulates cancer cell migration through SDF-1/CXCR4 axis and promotes tumour development by increasing neovascularization. *Cancer Lett* 2017, 395:11-19.
36. Conley-LaComb MK, Saliganan A, Kandagatla P, Chen YQ, Cher ML, Chinni SR: PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling. *Mol Cancer* 2013, 12(1):85.
37. Kan C, Vargas G, Pape FL, Clezardin P: Cancer Cell Colonisation in the Bone Microenvironment. *Int J Mol Sci* 2016, 17(10).
38. Barbieri A, Bimonte S, Palma G, Luciano A, Rea D, Giudice A, Scognamiglio G, La Mantia E, Franco R, Perdona S *et al*: The stress hormone norepinephrine increases migration of prostate cancer cells in vitro and in vivo. *Int J Oncol* 2015, 47(2):527-534.
39. Zhang P, He X, Tan J, Zhou X, Zou L: beta-arrestin2 mediates beta-2 adrenergic receptor signaling inducing prostate cancer cell progression. *Oncol Rep* 2011, 26(6):1471-1477.

40. Braadland PR, Ramberg H, Grytli HH, Tasken KA: beta-Adrenergic Receptor Signaling in Prostate Cancer. *Front Oncol* 2014, 4:375.
41. Yu J, Cao Q, Mehra R, Laxman B, Yu J, Tomlins SA, Creighton CJ, Dhanasekaran SM, Shen R, Chen G *et al*: Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. *Cancer Cell* 2007, 12(5):419-431.
42. Lee WC, Guntur AR, Long F, Rosen CJ: Energy Metabolism of the Osteoblast: Implications for Osteoporosis. *Endocr Rev* 2017, 38(3):255-266.
43. Krebs AM, Mitschke J, Lasierra Losada M, Schmalhofer O, Boerries M, Busch H, Boettcher M, Mougiakakos D, Reichardt W, Bronsert P *et al*: The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. *Nat Cell Biol* 2017, 19(5):518-529.
44. Pietila M, Ivaska J, Mani SA: Whom to blame for metastasis, the epithelial-mesenchymal transition or the tumor microenvironment? *Cancer Lett* 2016, 380(1):359-368.
45. Sun YX, Schneider A, Jung Y, Wang J, Dai J, Wang J, Cook K, Osman NI, Koh-Paige AJ, Shim H *et al*: Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. *J Bone Miner Res* 2005, 20(2):318-329.
46. Shan M, Qin J, Jin F, Han X, Guan H, Li X, Zhang J, Zhang H, Wang Y: Autophagy suppresses isoprenaline-induced M2 macrophage polarization via the ROS/ERK and mTOR signaling pathway. *Free Radic Biol Med* 2017, 110:432-443.
47. Su F, Zhang W, Chen Y, Ma L, Zhang H, Wang F: Significance of hypoxia-inducible factor-1alpha expression with atrial fibrosis in rats induced with isoproterenol. *Exp Ther Med* 2014, 8(6):1677-1682.
48. Park SY, Kang JH, Jeong KJ, Lee J, Han JW, Choi WS, Kim YK, Kang J, Park CG, Lee HY: Norepinephrine induces VEGF expression and angiogenesis by a hypoxia-inducible factor-1alpha protein-dependent mechanism. *Int J Cancer* 2011, 128(10):2306-2316.
49. Lu H, Liu X, Guo F, Tan S, Wang G, Liu H, Wang J, He X, Mo Y, Shi B: Impact of beta-blockers on prostate cancer mortality: a meta-analysis of 16,825 patients. *Onco Targets Ther* 2015, 8:985-990.
50. Assayag J, Pollak MN, Azoulay L: Post-diagnostic use of beta-blockers and the risk of death in patients with prostate cancer. *Eur J Cancer* 2014, 50(16):2838-2845.
51. Yap A, Lopez-Olivo MA, Dubowitz J, Pratt G, Hiller J, Gottumukkala V, Sloan E, Riedel B, Schier R: Effect of beta-blockers on cancer recurrence and survival: a meta-analysis of epidemiological and perioperative studies. *Br J Anaesth* 2018, 121(1):45-57.

## Supplemental Files

### Figure S1. Effect of CM from osteoblasts on proliferation of prostate cancer cells

(A) PC-3 cells were cultured with CM from MC3T3 E1 osteoblast cell lines treated with or without ISO for 24 h, and cell proliferation was detected by CCK-8. (B) PC-3 cells were cultured with CM from primary osteoblasts treated with or without ISO for 24 h, and cell proliferation was detected by CCK-8. (C) DU145 cells were cultured with CM from MC3T3 E1 osteoblast cell lines treated with or without ISO for 24 h, and

cell proliferation was detected by CCK-8. (D) DU145 cells were cultured with CM from primary osteoblasts treated with or without ISO for 24 h, and cell proliferation was detected by CCK-8. Data represent the mean  $\pm$  SEM, n.s, not significant, CM, conditioned medium.


### **Figure S2. Effect of LY2510924 on migration and invasion of prostate cancer cells induced by osteoblasts triggered by ISO.**

(A) Migration of PC-3 and DU145 cells were measured over 12 h in the co-culture with MC3T3E1 osteoblasts in response to 10  $\mu$ M ISO with or without 10 nM LY2510924, a CXCR4 antagonist (top). Quantification of relative migration (bottom) ( $n = 3$ ). (B) Invasion of PC-3 and DU145 cells were measured over 24 h in the co-culture with MC3T3E1 osteoblasts in response to 10  $\mu$ M ISO with or without 10 nM LY2510924 (top). Quantification of relative invasion (right) ( $n = 3$ ). (C) Migration of PC-3 and DU145 cells were measured over 12 h in the co-culture with primary osteoblasts and the experimental procedures were similar to (A) (top). Quantitative analysis of relative cell migration (bottom) ( $n = 3$ ). (D) Invasion of PC-3 and DU145 cells were measured over 24 h in the co-culture with primary osteoblasts and the experimental procedures were similar to (B) (top). Quantitative analysis of relative cell invasion (bottom) ( $n = 3$ ). Scales bars, 100  $\mu$ m; Data represent the mean  $\pm$  SEM.  $**p < 0.01$ ,  $***p < 0.001$ , and  $****p < 0.0001$ .

### **Figure S3. Effect of CM from osteoblasts on EMT of prostate cancer cells**


(A and B) PC-3 and DU145 cells were treated with CM from MC3T3E1 and primary osteoblasts in response to ISO with or without LY2510924 for 24 h, and expression of E-cadherin and Vimentin were detected by Western blotting ( $n = 2$ ). (C and D) EMT-related biomarkers expression of PC-3 and DU145 were detected by qRT-PCR. Data represent the mean  $\pm$  SEM.  $**p < 0.01$ ,  $****p < 0.0001$ , n.s, not significant, CM, conditioned medium.

## **Figures**



**Figure 1**

Effect of isoproterenol (ISO) on migration and invasion of prostate cancer cells. (A) Migration of PC-3 and DU145 cells were measured by Boden chamber transwell over 12 h in the presence or absence of 10  $\mu$ M ISO (left); Quantification of relative migratory cells of five distinct images (right) (n = 3); (B) Invasion of PC-3 and DU145 cells were measured by Boden chamber transwell over 24 h in the presence or absence of 10  $\mu$ M ISO (left); Quantification of relative invasion (right) (n = 3). Scales bars, 100  $\mu$ m; Results are shown as mean  $\pm$  SEM; n.s. not significant; Con: Control.



**Figure 2**


Effect of osteoblasts pretreated with ISO on migration and invasion of prostate cancer cells. (A) Schematic of the MC3T3 E1/primary osteoblast-PC-3/DU145 co-culture transwell migration and invasion assays. (B) Migration and invasion of PC-3 and DU145 cells were measured over 12 h and 24 h, respectively, in the co-culture with MC3T3 E1 with or without 10  $\mu$ M ISO, or PC-3 and DU145 cells were prior to the addition of 10  $\mu$ M propranolol (Pro), a non-selective  $\beta$ AR antagonist, for 30 min in order to

block  $\beta$ AR signaling in cancer cells (left). Quantitative analysis of relative cell migration and invasion (n = 3) (right). (C) Migration and invasion of PC-3 and DU145 cells were measured over 12 h and 24 h, respectively, in the co-culture with primary osteoblasts and the experimental procedures were similar to (B) (left). Quantification of relative migration and invasion (right) (n = 3). Scales bars, 100  $\mu$ m; Data represent the mean  $\pm$  SEM. \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001, and n.s. not significant.



### Figure 3

$\beta$ 2AR blockage of osteoblasts triggered by ISO inhibits migration and invasion of prostate cancer cells. (A) Migration and invasion of PC-3 and DU145 cells were measured over 12 h and 24 h, respectively, in the co-culture with MC3T3E1 osteoblasts with or without 10  $\mu$ M ISO, or with 10  $\mu$ M ISO combined with 50  $\mu$ M ICI 118,551, a  $\beta$ 2-adrenergic receptor antagonist (left). Quantification of relative migration and invasion (right) (n = 3). (B) Migration and invasion of PC-3 and DU145 cells were measured over 12 h and 24 h, respectively, in the co-culture with primary osteoblasts and the experimental procedures were similar to (A) (left). Quantitative analysis of relative cell migration and invasion (right) (n = 3). Scales bars, 100  $\mu$ m; Data represent the mean  $\pm$  SEM. \*\*p < 0.05, \*\*\*p < 0.01, and \*\*\*\*p < 0.001.



**Figure 4**

Osteoblasts pretreated with ISO induce EMT of prostate cancer cells. (A) E-cadherin and Vimentin of EMT markers were measured by Western blotting in PC-3 and DU145 cells treated with or without 10 $\mu$ M ISO for 24 h (left). Quantitative analysis of relative expression (n = 3) (middle and right). (B) E-cadherin and Vimentin were measured by Western blotting in PC-3 and DU145 cells co-cultured with MC3T3E1 cells pretreated with or without 10 $\mu$ M ISO, or 10 $\mu$ M ISO combined with 50 $\mu$ M ICI118,551, for 24 h (up).

Quantitative analysis of relative expression (n = 3) (bottom). (C) E-cadherin and Vimentin were measured by Western blotting in PC-3 and DU145 cells co-cultured with primary osteoblasts pretreated with or without ISO, or 10μM ISO combined with 50μM ICI118,551 (up). Quantitative analysis of relative expression (n = 3) (bottom). Data represent the mean ± SEM. \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001, and n.s. not significant.





Figure 5


ISO increases the secretion of CXCL12 via  $\beta$ 2AR-HIF-1 $\alpha$  in osteoblasts. qRT-PCR assay for metastasis related genes in MC3T3E1 (A) and primary osteoblasts (B) treated with 10 $\mu$ M ISO for 12 h. The data are shown as fold changes compared to that in the control groups (n = 3). (C) CXCL12 level was detected by ELISA in MC3T3E1 and primary osteoblasts treated with 10 $\mu$ M ISO for 24 h. (n = 4). (D) HIF-1 $\alpha$  expression and quantification were determined by Western blotting in MC3T3E1 and primary osteoblasts treated with 10 $\mu$ M ISO (n = 3). (E) HIF-1 $\alpha$  expression and quantification were determined by Western blotting in MC3T3E1 and primary osteoblasts treated with 10  $\mu$ M ISO combined with or without 50  $\mu$ M ICI118,551 for 24 h (n = 3). (F) CXCL12 level was detected by ELISA in MC3T3E1 and primary osteoblasts treated with ISO combined with or without YC-1, a HIF-1 $\alpha$  antagonist, for 24 h (n = 4). (G) MC3T3E1 and primary osteoblasts were transfected with siRNAs of HIF-1 $\alpha$  or control siRNAs for 24 h and then stimulated with ISO for 24 h. Expression of HIF-1 $\alpha$  were detected by Western blotting (left) (n = 2), and CXCL12 level was detected by ELISA (right) (n = 4). Data represent the mean  $\pm$  SEM. \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001, \*\*\*\*p < 0.0001 and n.s. not significant.



**Figure 6**

Effects of HIF-1 $\alpha$ -CXCL12 signaling in osteoblasts on migration and invasion of prostate cancer cells induced by osteoblasts. (A) Schematic of the MC3T3 E1/primary osteoblast-PC-3/DU145 co-culture transwell migration and invasion assays. (B) PC-3/DU145 cells and primary osteoblasts were transfected with siRNAs of CXCR4 and HIF-1 $\alpha$  overexpression plasmid, respectively, for 48 h and then expression of CXCR4 (left) and HIF-1 $\alpha$  (right) were detected by qRT-PCR and Western blot, respectively (n = 3). (C)

Migration and invasion of PC-3 and DU145 cells were measured over 12 h and 24 h, respectively, in the co-culture with MC3T3E1 osteoblasts with overexpression of HIF-1 $\alpha$  or combined with knockdown of CXCR4 in PC-3 and DU145 cells (left). Quantification of relative migration and invasion (right) (n = 3). (D) Migration and invasion of PC-3 and DU145 cells were measured over 12 h and 24 h, respectively, in the co-culture with primary osteoblasts with overexpression of HIF-1 $\alpha$  or combined with knockdown of CXCR4 in PC-3 and DU145 cells (left). Quantification of relative migration and invasion (right) (n = 3). Scales bars, 100  $\mu$ m; Data represent the mean  $\pm$  SEM. \*\*p < 0.01, \*\*\*\*p < 0.0001; OE: overexpression.



**Figure 7**

Schematic illustration for ISO induced-osteoblasts activation and migration/invasion of prostate cancer cells. Osteoblasts respond to  $\beta$ 2AR signaling activated by ISO to produce CXCL12 through upregulating the expression of HIF-1 $\alpha$ . Osteoblast-driven CXCL12 binds to CXCR4 to promote migration and invasion as well as EMT of prostate cancer cells.  $\beta$ 2AR,  $\beta$ 2 adrenergic receptor; ISO, isoproterenol; CXCL12, chemokine (C-X-C motif) ligand 12; CXCR4, chemokine (C-X-C motif) receptor type 4; HIF-1 $\alpha$ , hypoxia inducible factor-1 $\alpha$ ; EMT, epithelial-mesenchymal transition.

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [FigureS2.tif](#)
- [FigureS1.tif](#)
- [FigureS3.tif](#)
- [TheARRIVEGuidelinesChecklist.pdf](#)